Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn

Affiliations

Science Blogs
ACI Profile for Alan Kotok
Featured in Alltop

Project Aims to Boost Ebola Drug Production

Karen McDonald (University of California, Davis)

31 December 2014. A research team at University of California in Davis aims to find new ways of boosting production capacity of the experimental Ebola drug ZMapp. The 1-year project, led by UC-Davis chemical engineering and materials science professor Karen McDonald, is funded by a $200,000 rapid-response grant . . . → Read More: Project Aims to Boost Ebola Drug Production

Pump Device Shown to Deliver Parkinson’s Drug

3-D brain wiring illustration (NIH)

30 December 2014. A clinical trial testing a pump worn by Parkinson’s disease patients shows the device can continuously deliver drugs under the skin to treat severe forms of the disorder, which today requires a surgical implant. The pump made by NeuroDerm Ltd. in Rehovot, Israel is designed to . . . → Read More: Pump Device Shown to Deliver Parkinson’s Drug

Vaccine Combo Produces Ricin, Anthrax Antibodies

Anthrax spores (U.S. Food and Drug Administration)

29 December 2014. Tests of a vaccine to prevent ricin and anthrax poisoning shows it produces long-lasting antibodies against both toxins, making a single vaccine against both bioterror agents more feasible. Results of a study by biotechnology company Soligenix Inc. in Princeton, New Jersey are reported in . . . → Read More: Vaccine Combo Produces Ricin, Anthrax Antibodies

Merry Christmas/Feliz Navidad

Science and Enterprise is taking a break tomorrow and Friday for Christmas. In the spirit of the season, here is a video from a group of talented, yet little-known musicians taking part of an initiative called Playing for Change. That organization finds unknown, talented musicians worldwide, many of whom are playing on the street or . . . → Read More: Merry Christmas/Feliz Navidad

Early Trial Underway Testing Brain Cancer Drug

(Research.gov)

24 December 2014. Kinex Pharmaceuticals, a developer of cancer therapies, began an early-stage clinical trial of an experimental treatment for tumors of support cells in the brain. The Buffalo, New York biotechnology company says the first patient received the drug code-named KX2-361 in the trial taking place at Roswell Park Cancer Institute, also . . . → Read More: Early Trial Underway Testing Brain Cancer Drug

FDA Approves New Influenza Treatment

Influenza ultrastructure illustration (Dan Higgins, CDC)

23 December 2014. The U.S. Food and Drug Administration approved yesterday a drug to treat influenza infections in adults. The treatment, Rapivab, is a small molecule drug made by BioCryst Pharmaceuticals in Durham, North Carolina.

BioCryst designs and develops therapies that block enzymes involved in infectious and inflammatory . . . → Read More: FDA Approves New Influenza Treatment

Trial Testing Biologic Treatment for Hepatitis D

Liver (National Library of Medicine)

22 December 2014. An intermediate-stage clinical trial testing a biologic treatment made by Eiger BioPharmaceuticals Inc. shows lower hepatitis D virus levels among patients taking the treatment compared to a placebo. The San Carlos, California company says the treatment, called lonafarnib, also received orphan drug status by regulatory authorities . . . → Read More: Trial Testing Biologic Treatment for Hepatitis D

3-D Tissue Assembly System Designed

Jeffrey Morgan (Brown University)

22 December 2014. Medical and engineering researchers at Brown University in Providence developed a system that puts together synthetic tissue components into larger tissue assemblies, a step in the creation of synthetic organs. A description of the system from the lab of Brown bioengineering professor Jeffrey Morgan was published on . . . → Read More: 3-D Tissue Assembly System Designed

Lilly, Biotech Partner on Fast-Acting Insulin Analog

(National Institutes of Health)

19 December 2014. The pharmaceutical company Eli Lilly and Company and biotechnology company Adocia are collaborating on commercial development of Adocia’s fast-acting synthetic insulin product. Adocia, based in Lyon, France, can gain as much as $570 million in the deal, not counting royalties on future sales.

Adocia develops enhanced formulations . . . → Read More: Lilly, Biotech Partner on Fast-Acting Insulin Analog

Juno Therapeutics Raises $265 Million in IPO

(A. Kotok)

19 December 2014. Juno Therapeutics, a biotechnology company spun-off from research labs in Seattle and New York, raised some $265 million yesterday in its initial public stock offering. The Seattle enterprise developing cancer therapies that harness the immune system issued 11 million shares of common stock priced at $24.00, and trades on . . . → Read More: Juno Therapeutics Raises $265 Million in IPO